Amneal Pharmaceuticals is a healthcare company focused on developing, manufacturing, and distributing generic and specialty pharmaceuticals. Its core products include a range of generic medications across various therapeutic areas, as well as branded products. The company operates in segments such as generics, specialty pharmaceuticals, and over-the-counter products. Major revenue sources stem from sales of generic drugs and specialty treatments, catering to both retail and institutional markets.
The investment profile of Amneal Pharmaceuticals is more aligned with value investors, given its current market position and financial metrics. The company has shown fluctuations in revenue, indicating potential challenges in growth. Investors may find it suitable for a balanced approach, considering its established presence in the pharmaceutical sector.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-08 | Hold | Buy | Positive EPS surprise, but mixed momentum signals. |
| 2026-08-29 | Buy | Hold | Mixed performance; cautious due to recent negative momentum. |
| 2026-08-02 | Hold | Buy | Positive momentum, but uncertain analyst signals. |
| 2026-06-27 | — | Hold | Recent performance strong, but fundamentals show weakness. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-09-23 | Oppenheimer | Update | — → 27 | 19.5 |
| 2026-09-17 | Barclays | Target Raised | 16 → 20 | 18.08 |
| 2026-09-09 | Leerink Partners | Update | — → 23 | 17.05 |
| 2026-08-03 | UBS | Target Raised | 23 → 25 | 18.32 |
| 2026-07-31 | Goldman Sachs | Target Raised | 19 → 21 | 18.5 |
| 2026-07-15 | UBS | Target Raised | 19 → 23 | 17.095 |
| 2026-05-20 | Barclays | Target Raised | 15 → 16 | 11.81 |
| 2026-04-17 | UBS | Update | — → 19 | 13.09 |
| 2026-03-02 | Truist Financial | Target Raised | — → 17 | 13.453 |
| 2026-01-07 | Truist Financial | Target Raised | 14 → 15 | 12.99 |
| 2025-12-08 | Barclays | Update | — → 15 | 11.87 |
